NCT04930562View on ClinicalTrials.gov

Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

June 10, 2022

Study Completion Date

December 10, 2022

Conditions
GVHD, Chronic
Interventions
DRUG

BN101

BN101 is an orally ROCK2 selective inhibitor

Trial Locations (7)

215006

The First Affiliated Hospital of Soochow University, Suzhou

Unknown

Peking University People's Hospital, Beijing

Xinqiao Hospital, Army Medical University, Chongqing

Guangzhou First People's Hospital, Guangzhou

Nanfang Hospital, Guangzhou

Zhujiang Hospital of Southern Medical University, Guangzhou

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
lead

BioNova Pharmaceuticals (Shanghai) LTD.

INDUSTRY